ProPhase Labs, Inc. Restricted Cash, Current
ProPhase Labs, Inc. (PRPH) had Restricted Cash, Current of $593.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2024-11-13
- 2024-09-30: Restricted Cash, Current $593.00K.
- 2024-06-30: Restricted Cash, Current $585.00K.
- 2024-03-31: Restricted Cash, Current $561.00K.
- 2023-12-31: Restricted Cash, Current $540.00K.
| Period end | Restricted Cash, Current |
|---|---|
| 2024-09-30 | $593.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $585.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $561.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $540.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |